Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 2/20 | 0.37 |
| ▸ | PSMD14 | O00487 | 2/20 | 0.37 |
| ▸ | COPS5 | Q92905 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 2/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4640948 | 0.86 | PDGFRB (0.40) | SMN1; SMN2KDM4EMEN1KMT2ASYK | |
| SCHEMBL3050683 | 0.78 | BACE1 (0.50) | SMN1; SMN2KDM4EPSMD14COPS5ALDH1A1 | |
| SCHEMBL3704824 | 0.77 | KDM4E (0.62) | KDM4EMEN1KMT2ANPC1TSHR | |
| SCHEMBL19343131 | 0.77 | KDM4E (0.44) | SMN1; SMN2KDM4EMEN1KMT2APSMD14 | |
| SCHEMBL3060889 | 0.77 | KDM4E (0.37) | SMN1; SMN2KDM4EPSMD14COPS5NPC1 | |
| SCHEMBL3064498 | 0.77 | NR4A2 (0.46) | SMN1; SMN2KDM4EPSMD14COPS5ALDH1A1 | |
| SCHEMBL3718782 | 0.77 | KDM4E (0.62) | KDM4EPSMD14COPS5PARP1ABCB1 | |
| SCHEMBL1666214 | 0.77 | TET2 (0.44) | SMN1; SMN2KDM4EMEN1KMT2APSMD14 | |
| SCHEMBL12487794 | 0.77 | KDM4E (0.44) | KDM4ESYKPSMD14COPS5NPC1 | |
| SCHEMBL14923574 | 0.77 | KDM4E (0.38) | SMN1; SMN2KDM4EMEN1KMT2APSMD14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171431-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2025-05-29 | — | — | US | disclosed |
| WO-2025030163-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2025-02-06 | — | — | WO | disclosed |
| US-20230278984-A1 | UREA DERIVATIVES AS PYRUVATE KINASE ACTIVATORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-09-07 | — | — | US | disclosed |
| US-11744246-B2 | Preparation of mammalian oocyte for fertilization via a soluble human PH20 hyaluronidase polypeptide | SYNGENTA PARTICIPATIONS AG (CH) | 2023-09-05 | — | — | US | disclosed |
| EP-4188542-A1 | UREA DERIVATIVES AS PYRUVATE KINASE ACTIVATORS | Global Blood Therapeutics, Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
| US-11584740-B2 | Microbiocidal quinoline (thio)carboxamide derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2023-02-21 | — | — | US | disclosed |
| CN-110603253-B | Heteroaryl phenylamino quinolines and analogs | 拜耳公司 | 2023-01-20 | — | — | CN | disclosed |
| EP-3853207-B1 | MICROBIOCIDAL QUINOLINE CARBOXAMIDE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2022-10-19 | — | — | EP | disclosed |
| US-11457629-B2 | Heteroarylphenylaminoquinolines and analogues | BAYER AKTIENGESELLSCHAFT (DE) | 2022-10-04 | — | — | US | disclosed |
| US-11440888-B2 | Microbiocidal quinoline carboxamide derivatives | SYNGENTA CROP PROTECTION AG (CH) | 2022-09-13 | — | — | US | disclosed |
| US-10000482-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| WO-2014060113-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2014-04-24 | — | — | WO | disclosed |
| WO-2014060112-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2014-04-24 | — | — | WO | disclosed |
| US-20090186918-A1 | Triazole Compounds as Lipoxygenase Inhibitors | BIOLIPOX AB (SE) | 2009-07-23 | — | — | US | disclosed |
| CN-101300236-A | Triazole compounds as lipoxygenase inhibitors | BIOLIPOX AB (SE) | 2008-11-05 | — | — | CN | disclosed |
| EP-1943234-A1 | TRIAZOLE COMPOUNDS AS LIPOXYGENASE INHIBITORS | Biolipox AB (SE) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007051982-A1 | TRIAZOLE COMPOUNDS AS LIPOXYGENASE INHIBITORS | BIOLIPOX AB (SE) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | SMN1; SMN2 882/4885KDM4E 1662/4885MEN1 544/4885 |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | SMN1; SMN2 835/4885KDM4E 1409/4885MEN1 1218/4885 |
| US-20230278984-A1 | UREA DERIVATIVES AS PYRUVATE KINASE ACTIVATORS | PKM, PDK1, PDK2 | SMN1; SMN2 722/4885KDM4E 1378/4885MEN1 4531/4885 |
| US-11440888-B2 | Microbiocidal quinoline carboxamide derivatives | IDO1, TLR1, TLR5 | SMN1; SMN2 4663/4885KDM4E 1655/4885MEN1 2071/4885 |
| US-11744246-B2 | Preparation of mammalian oocyte for fertilization via a soluble human PH20 hyaluronidase polypeptide | PHF20, FUCA1, ZP1 | SMN1; SMN2 4536/4885KDM4E 4050/4885MEN1 502/4885 |
| US-11457629-B2 | Heteroarylphenylaminoquinolines and analogues | PIK3C3, CYP4X1, CYP1A2 | SMN1; SMN2 4635/4885KDM4E 892/4885MEN1 2836/4885 |
| US-20250171431-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | IGF1R, TRHR, TSHR | SMN1; SMN2 4102/4885KDM4E 2811/4885MEN1 160/4885 |
| US-11584740-B2 | Microbiocidal quinoline (thio)carboxamide derivatives | IFNG, TLR1, IDO1 | SMN1; SMN2 4749/4885KDM4E 1828/4885MEN1 2747/4885 |
| US-20090186918-A1 | Triazole Compounds as Lipoxygenase Inhibitors | ALOX15, ALOX15B, ALOX12 | SMN1; SMN2 4658/4885KDM4E 3030/4885MEN1 4656/4885 |
| US-10000482-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | SMN1; SMN2 986/4885KDM4E 1645/4885MEN1 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.